Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Lung Cancer. 2011 Feb;71(2):217–223. doi: 10.1016/j.lungcan.2010.05.012

Table 2.

For overall survival in advanced NSCLC, effect of number of chemotherapy agents in frontline treatment regimen on % of patients in rapid-decay phase and on rapid-decay phase half-life

Therapy No. studies % rapid-decay phase P* Rapid phase t1/2** P*
Median Range Median Range
Best supportive care 6 96.7 82.6-100 0.006 4.4 3.8-4.7 0.0008
Single Agent 5 94.8 66.4-100 4.9 1.5-7.1
Two Drugs 28 100 12.9-100 7.5 2.5-11.5
≥ Three drugs 7 100 100-100 6.8 4.6-12.2
*

Kruskal-Wallis comparison of groups

**

months